• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

病例报告：使用多巴胺能药物联合方案治疗 cilta-cabtagene autoleucel 引起的帕金森病。

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.

机构信息

Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.

Division of Multiple Myeloma, Department of Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

出版信息

Front Immunol. 2024 Sep 20;15:1444010. doi: 10.3389/fimmu.2024.1444010. eCollection 2024.

DOI:10.3389/fimmu.2024.1444010
PMID:39372422
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11449727/
Abstract

We report on a patient with ciltacabtagene autoleucel-induced movement and neurocognitive toxicity, which was refractory to immunosuppression but responsive to combination dopaminergic therapy (carbidopa/levodopa, ropinirole, amantadine). Response was seen upon both initial treatment and rechallenge after unintended withdrawal. This is the first report of a successful symptomatic treatment of this well-described neurotoxic syndrome.

摘要

我们报告了一例 cilta-cabtagene autoleucel 诱导的运动和神经认知毒性患者，该患者对免疫抑制治疗无效，但对联合多巴胺能治疗（卡比多巴/左旋多巴、罗匹尼罗、金刚烷胺）有反应。在意外停药后再次治疗时，初始治疗和再次挑战均有反应。这是首例成功治疗这种明确描述的神经毒性综合征的症状性治疗报告。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb1/11449727/44325bae0456/fimmu-15-1444010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb1/11449727/44325bae0456/fimmu-15-1444010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb1/11449727/44325bae0456/fimmu-15-1444010-g001.jpg

相似文献

1
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.病例报告：使用多巴胺能药物联合方案治疗 cilta-cabtagene autoleucel 引起的帕金森病。
Front Immunol. 2024 Sep 20;15:1444010. doi: 10.3389/fimmu.2024.1444010. eCollection 2024.
2
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.临床医生和管理人员对复发或难治性多发性骨髓瘤患者门诊应用 cilta-cabtagene autoleucel 的看法。
Front Immunol. 2024 Jun 10;15:1405452. doi: 10.3389/fimmu.2024.1405452. eCollection 2024.
3
Initiating therapy for Parkinson's disease.启动帕金森病治疗
Neurology. 1998 Jun;50(6 Suppl 6):S18-22; discussion S44-8. doi: 10.1212/wnl.50.6_suppl_6.s18.
4
A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.一项关于新型D2激动剂罗匹尼罗治疗左旋多巴治疗的帕金森病患者运动波动的安慰剂对照研究。
Adv Neurol. 1996;69:531-4.
5
High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.高剂量培高利特单一疗法治疗严重左旋多巴诱发的运动障碍。
Mov Disord. 1996 May;11(3):327-9. doi: 10.1002/mds.870110319.
6
Augmentation of artistic productivity in Parkinson's disease.帕金森病患者艺术创造力的增强。
Mov Disord. 2006 Feb;21(2):285-6. doi: 10.1002/mds.20758.
7
Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.罗匹尼罗治疗帕金森病患者左旋多巴诱导的运动波动。
Clin Neuropharmacol. 1996 Jun;19(3):234-45. doi: 10.1097/00002826-199619030-00005.
8
Amantadine-induced "vocal" myoclonus.金刚烷胺诱发的“发声性”肌阵挛。
Mov Disord. 1996 Jan;11(1):104-6. doi: 10.1002/mds.870110123.
9
Fracture risk associated with parkinsonism and anti-Parkinson drugs.帕金森病及抗帕金森药物相关的骨折风险。
Calcif Tissue Int. 2007 Sep;81(3):153-61. doi: 10.1007/s00223-007-9065-6. Epub 2007 Aug 20.
10
[Case of juvenile parkinsonism in pregnancy].[妊娠期青少年帕金森病病例]
Rinsho Shinkeigaku. 2006 Jun;46(6):400-3.

引用本文的文献

1
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.用于cilta-cel相关运动和神经认知毒性的鞘内化疗
Blood Adv. 2025 Jul 22;9(14):3613-3616. doi: 10.1182/bloodadvances.2024015721.

本文引用的文献

1
Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel.接受idecabtagene-vicleucel治疗的女性患者出现帕金森样神经毒性。
Hemasphere. 2024 Jul 25;8(7):e131. doi: 10.1002/hem3.131. eCollection 2024 Jul.
2
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.化疗诱导的 cilta-cabtagene autoleucel 相关运动和神经认知毒性逆转。
Blood. 2023 Oct 5;142(14):1248-1252. doi: 10.1182/blood.2023021429.
3
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
CARTITUDE 研究中接受 cilta-celgene autoleucel 治疗的多发性骨髓瘤患者的 CAR-T 神经毒性的发生率和管理。
Blood Cancer J. 2022 Feb 24;12(2):32. doi: 10.1038/s41408-022-00629-1.
4
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.BCMA 靶向 CAR-T 细胞治疗后出现以帕金森病为特征的神经认知和运动障碍。
Nat Med. 2021 Dec;27(12):2099-2103. doi: 10.1038/s41591-021-01564-7. Epub 2021 Dec 10.
5
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
6
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.帕金森病的左旋多巴治疗：药代动力学与药效学
Mov Disord. 2015 Jan;30(1):64-72. doi: 10.1002/mds.26082. Epub 2014 Dec 1.
7
Clinical pharmacokinetics of ropinirole.罗匹尼罗的临床药代动力学。
Clin Pharmacokinet. 2000 Oct;39(4):243-54. doi: 10.2165/00003088-200039040-00001.